Search Results

The Hon Greg Hunt MP, Minister for Health recently announced that TEVA Pharma Australia’s new treatment for the prevention of chronic migraine in adults, AJOVY®, will be listed on the Pharmaceutical Benefits Scheme (PBS).

In comparison to the pre-COVID-19 period, studies suggest people with migraine are experiencing close to a 60% increase in migraine frequency, and 60% increase in migraine severity.

Our ESG Progress: Four Perspectives

As a leading global pharmaceutical company, Teva provides essential medicines to millions of patients around the world every day. Our priorities remain focused on the health and well-being of our...

As a leading global pharmaceutical company, Teva provides essential medicines to millions of patients around the world every day. Our priorities remain focused on the health and well-being of our...

New preventive treatment for migraine now licensed in Australia

Following a successful global launch, Teva Australia has launched its new Branding into the market. This occurred at an industry event attended by over 150 attendees and was well received.

JERUSALEM-(BUSINESS WIRE)-Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that it has entered into a new $2.3 billion unsecured revolving credit facility, which replaces its existi...

When Ethiopia began to run out of cancer medicines to treat children, a race against time began to get crucial supplies to the country.

On February 8, 2018, we reported Teva's financial results for Q4 and full year 2017, and provided the outlook for 2018.